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Abstract
Background: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe
Alzheimer’s disease (AD), was developed to address the need for an additional treatment option for patients with
advanced AD. This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and
tolerability of increasing donepezil to 23 mg/d compared with continuing 10 mg/d.
Method: Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent
adverse events (AEs) and their relationship to treatment initiation; changes in weight, electrocardiogram, vital signs,
and laboratory parameters; and the incidence of premature study discontinuation. The analysis population (n =
1434) included all randomized patients who took at least 1 dose of study drug and had a postbaseline safety
assessment. To further examine the effect of transition from a lower to a higher donepezil dose, a pooled analysis
of safety data from 2 phase 3 trials of donepezil 5 mg/d and 10 mg/d was also performed.
Results: The safety population comprised 1434 patients: donepezil 23 mg/d (n = 963); donepezil 10 mg/d (n = 471);
completion rates were 71.1% and 84.7%, respectively. The most common AEs were nausea, vomiting, and diarrhea
(donepezil 23 mg/d: 11.8%, 9.2%, 8.3%; donepezil 10 mg/d: 3.4%, 2.5%, 5.3%, respectively). AEs that contributed most to
early discontinuations were vomiting (2.9% of patients in the 23 mg/d group and 0.4% in the 10 mg/d group), nausea
(1.9% and 0.4%), diarrhea (1.7% and 0.4%), and dizziness (1.1% and 0.0%). The percentages of patients with AEs in the 23
mg/d group, as well as the timing, type, and severity of these AEs, were similar to those seen in previous donepezil
trials with titration from 5 to 10 mg/d. Serious AEs were uncommon (23 mg/d, 8.3%; 10 mg/d, 9.6%).
Discussion: The 23 mg/d dose of donepezil was associated with typical cholinergic AEs, particularly
gastrointestinal-related AEs, similar to those observed in studies with a dose increase from 5 to 10 mg/d.
Conclusion: The good safety and predictable tolerability profile for donepezil 23 mg/d supports its favorable
risk/benefit ratio in patients with moderate to severe AD.
Trial RegistrationNCT00478205
Background
Efficacy and safety of once-daily donepezil 23 mg, an
acetylcholinesterase inhibitor (AChEI), were investigated
in a recent clinical trial involving 1467 randomized
patients with moderate to severe Alzheimer’s disease
(AD) (NCT00478205) [1]. Compared with patients who
continued taking donepezil 10 mg/d, those whose dose
was increased to donepezil 23 mg/d demonstrated a
significantly greater cognitive benefit on the Severe
Impairment Battery (SIB) after 6 months of treatment.
AChEIs as a class may cause cholinergic adverse
events (AEs). The most frequently occurring treatment-
related AEs are nausea, vomiting, and diarrhea, and the
frequency and severity of these effects are related to
dose [2,3]. Less common class-related AEs include vago-
tonic (eg, bradycardia, syncope), central nervous system
(eg, aggression, sleep disturbance), and parasympatheti-
cally mediated (eg, urinary incontinence) AEs [4,5]. Gas-
trointestinal (GI) AEs typically increase after dose
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frequency declines within a few weeks [3,4].
This report is a detailed presentation and analysis of
the safety and tolerability data from the previously pub-
lished clinical trial [1] comparing an increase in the
daily dose of donepezil from 10 mg/d to 23 mg/d with
continuation on 10 mg/d. These analyses substantively
extend the presentation of safety and tolerability
findings previously published. In addition, this paper
includes an analysis of pooled data from 2 previous dou-
ble-blind, placebo-controlled, 24-week trials in which
donepezil was initiated at 5 mg/d and titrated to 10 mg/d
[6,7] in order to further clarify the relationship between
dose transitions and AEs. The primary objective is
to help guide clinicians who are treating patients with
moderate to severe AD at this new dosage.
Methods
Objectives and study design
The protocol and informed-consent form were approved
by the independent ethics committee/institutional
review board at each independent research site and
conformed to the principles of the World Medical Asso-
ciation’s Declaration of Helsinki and all local regula-
tions. The study design was reviewed and deemed
appropriate by the US Food and Drug Administration
(FDA) and other global regulatory agencies.
The primary objective of the study reported by Farlow
et. al. [1] was to compare the efficacy and safety of esca-
lation to the higher donepezil dose (23 mg/d) versus
continuation on the 10 mg/d dose. The design and
methods of this study have been described previously
[1]. Briefly, this randomized, double-blind, parallel-
group study included patients with moderate to severe
AD (Mini-Mental State Examination [MMSE] score
0-20 at baseline) who had already been taking donepezil
10 mg/d for at least 3 months. Patients who were taking
memantine at doses of ≤ 20 mg/d for at least 3 months
prior to screening could enroll, provided they agreed to
maintain that dosage throughout the trial. Patients were
randomized 2:1 to either increase to donepezil 23 mg/d
or continue donepezil 10 mg/d for 24 weeks. Randomi-
zation was stratified by memantine use at baseline.
Safety analysis
Safety analyses comprised examination of the incidence,
severity, and timing of treatment-emergent AEs and their
relationship to treatment initiation; changes in weight,
electrocardiogram (ECG), vital signs, and laboratory para-
meters; and the incidence of premature discontinuation
from the study. Serious AEs were defined as those that
resulted in death or were life-threatening or required hos-
pitalization or prolongation of hospitalization, or created
persistent or significant disability/incapacity. Safety and
tolerability were assessed in the safety population
(n = 1434), which included all randomized patients who
took at least 1 dose of study drug and had at least 1 post-
baseline safety assessment. In addition to the planned
analyses described above, post hoc analyses were con-
ducted to examine safety and tolerability based on intrinsic
and extrinsic patient characteristics, including demo-
graphic variables. Age categories were selected to comply
with regulatory reporting guidelines and are limited at the
low and high ends by study entry criteria. Weight group-
ings were selected to provide both consistent ranges and
comparable numbers of subjects. The impact of concomi-
tant memantine use on AEs was also examined.
Analysis of pooled data from prior studies
To further compare the impact of titration from a lower
to a higher donepezil dose, a pooled analysis was
performed on previously published data from studies of
patients with mild to moderate AD newly receiving
donepezil [6,7]. All patients in both of these studies
received 5 mg/d or placebo during Week 1; from Week
2 until the end of the study, groups received placebo,
donepezil 5 mg/d, or donepezil 10 mg/d. The forced
dose titration took place on study Day 8. Data were ana-
lyzed for cumulative percentage of patients with AEs.
Results
Demographics and baseline characteristics
The baseline demographic profile of patients included in
the safety population of the study by Farlow et al. is shown
in Table 1. All baseline values were similar between the 2
treatment groups. Prior to baseline, patients in both treat-
ment groups had been taking donepezil for a mean (± SD)
of 110 (105) weeks (range, 10-606 weeks).
Patient disposition
Of 1467 patients in the 10 mg/d vs 23 mg/d study who
were randomized to treatment, 981 (66.9%) received
donepezil 23 mg/d and 486 (33.1%) received donepezil
10 mg/d. The safety population comprised 1434
patients: 963 in the donepezil 23 mg/d group and 471 in
the donepezil 10 mg/d group (Figure 1). Sixteen patients
(9 donepezil 23 mg/d and 7 donepezil 10 mg/d) discon-
tinued from the study prior to receiving the study drug
and 17 patients (9 donepezil 23 mg/d and 8 donepezil
10 mg/d) received at least 1 dose of study medication
but were not included in the safety population because
of lack of a postbaseline safety assessment. Completion
rates for the patients in the safety population were
71.1% and 84.7% in the 23 mg/d and 10 mg/d treatment
groups, respectively. AEs were the most common reason
for discontinuation (23 mg/d = 18.8%, 10 mg/d = 7.9%);
the AEs that contributed to the greatest number of early
discontinuations were vomiting, nausea, diarrhea, and
dizziness (Table 2).
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Overview
As has been reported previously [1], AEs were generally
more common in the 23 mg/d group, occurring in
73.7% of patients, compared with 63.7% of patients in
the donepezil 10 mg/d group (Table 3). Of patients who
experienced AEs, the majority (88.6% in the 23 mg/d
g r o u pa n d8 8 . 7 %i nt h e1 0m g / dg r o u p )h a dA E so f
mild to moderate severity. The most common AEs–the
only AEs that occurred in >5% of patients in either
group–were nausea, vomiting, diarrhea, and anorexia.
Overall, 125 (8.7%) patients experienced at least 1 ser-
ious AE during the study (Table 4). The incidence of
serious AEs was similar in the 23 mg/d group (8.3%)
a n dt h e1 0m g / dg r o u p( 9 . 6 % ) .S e r i o u sA E st h a tw e r e
deemed possibly or probably related to study drug were
also similar in frequency in the 23 mg/d group (2.8%)
and the 10 mg/d group (2.3%). There were 13 deaths
during the study or within 30 days of the study end: 8
(0.8%) in the donepezil 23 mg/d group and 5 (1.1%) in
Table 1 Baseline demographic profile of patients
in the safety population
Donepezil 23 mg/d
(n = 963)
Donepezil 10 mg/d
(n = 471)
Age (years), mean
(SD)
73.9 (8.53) 73.8 (8.56)
Gender, n (%)
Male 356 (37.0) 177 (37.6)
Female 607 (63.0) 294 (62.4)
Race, n (%)
White 708 (73.5) 346 (73.5)
Asian/Pacific 161 (16.7) 87 (18.5)
Hispanic 67 (7.0) 26 (5.5)
Black 22 (2.3) 9 (1.9)
Other 5 (0.5) 3 (0.6)
Weight (kg)
<55 218 (22.6) 111 (23.6)
≥55 744 (77.3) 360 (76.4)
Missing 1 (0.1) 0 (0.0)
Concomitant
memantine use, n (%)
Memantine 352 (36.6) 168 (35.7)
None 611 (63.4) 303 (64.3)
Prior donepezil use
(weeks)
Mean (SD) 112.2 (108.2) 104.8 (99.0)
Range 9.9-574.6 10.4-606.4
Baseline MMSE
Mean (SD) 13.1 (4.99) 13.0 (4.75)
Randomized
(N = 1467)
Safety population
(n = 1434)
Reasons for discontinuation
• AE (18.8%)
• Lack of efficacy (0.1%)
• All other (10.2%)
Reasons for discontinuation
• AE (8.1%)
• Lack of efficacy (0%)
• All other (7.2%)
Screened 
(N = 2186)
Completed
(n = 685)
Withdrawn
(n = 278)
Completed
(n = 399)
Withdrawn
(n = 72)
Donepezil 23 mg/d
(n = 963)
Donepezil 10 mg/d
(n = 471)
Figure 1 Patient disposition.
Table 2 AEs leading to discontinuation that occurred in
>1.0% of patients in the 23 mg/d treatment group
Preferred Term Donepezil 23 mg/d,
n (%)
(n = 963)
Donepezil 10 mg/d,
n (%)
(n = 471)
Total 179 (18.6) 37 (7.9)
Vomiting 28 (2.9) 2 (0.4)
Nausea 18 (1.9) 2 (0.4)
Diarrhea 16 (1.7) 2 (0.4)
Dizziness 11 (1.1) 0 (0.0)
Table 3 AEs that occurred in ≥ 2% of patients in the
donepezil 23 mg/d group and at higher frequency than
in the donepezil 10 mg/d group
Preferred term Donepezil 23 mg/d
(n = 963)
Donepezil 10 mg/d
(n = 471)
Percentage of patients
with at least 1 AE
73.7 63.7
Nausea 11.8 3.4
Vomiting 9.2 2.5
Diarrhea 8.3 5.3
Anorexia 5.3 1.7
Dizziness 4.9 3.4
Weight decreased 4.7 2.5
Urinary tract infection 4.4 4.0
Headache 4.3 3.2
Fall 4.0 3.8
Agitation 3.9 3.8
Insomnia 3.4 2.3
Bradycardia 2.7 0.6
Sinus bradycardia 1.1 0.0
Aggression 2.7 2.5
Urinary incontinence 2.5 1.3
Fatigue 2.4 0.8
Asthenia 2.1 0.6
Contusion 2.1 0.2
Somnolence 2.1 1.1
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related to the study medication.
AEs of interest
Of particular interest are those AEs that have potentially
important clinical consequences. In the present analysis,
for this large cohort of patients with moderate to severe
AD, this includes those AEs commonly associated with
more advanced AD, such as falls and psychiatric symp-
toms, and those that are cholinergic-related, including
GI bleeding, bradycardia, and weight loss.
GI bleeding There was a higher incidence of GI bleed-
ing (in total, including the following terms: GI hemor-
rhage, hematemesis, hematochezia, hemorrhagic
diarrhea, melena, and rectal bleeding) in the 23 mg/d
group (1.1%) than in the 10 mg/d group (0.6%). Of the
14 GI bleeding events, all 7 serious cases occurred in
the 23 mg/d group. Of these, 3 were considered possibly
related to study medication; in 2 of these cases the
patient was discontinued from the study.
Bradycardia There were 27 (2.8%) cases of bradycardia
in the 23 mg/d group (including 11 cases of sinus
bradycardia, which is a distinct term in the Medical
Dictionary for Regulatory Activities), compared with 3
(0.6%) cases in the 10 mg group. All but 1 of the brady-
cardia events in the 23 mg/d group were mild or moder-
ate in severity; none of the events in the 10 mg/d group
was severe and only 4 of the 23 mg/d events were defined
as serious. Of the 4 patients who had a serious event,
2 stayed on drug and completed the study, 2 discontin-
ued the study; all had resolution of their bradycardia. In
the month preceding or following the bradycardia event,
2 cases were associated with dizziness, 1 with a fall, and
none with syncope. Eight patients in the 23 mg/d group
and no patients in the 10 mg/d group discontinued from
the study because of bradycardia.
Weight loss W e i g h tl o s sw a sr e p o r t e da sa nA Em o r e
frequently in the donepezil 23 mg/d group (4.7%) than
in the donepezil 10 mg/d group (2.5%). By the end of
the study, 8.4% of patients in the donepezil 23 mg/d
group experienced a weight decrease of ≥ 7%, compared
with 4.9% of those in the 10 mg/d group.
Falls The percentage of patients experiencing falls was
similar in the 23 mg/d and 10 mg/d groups (4.0% vs
3.8%). Twenty-nine of 39 cases (74.4%) in the 23 mg/d
group and 13 of 18 cases (72.2%) in the 10 mg/d group
were not considered related to study medication.
Psychiatric symptoms In the 2 treatment groups, there
were similar rates of agitation (3.9% in the 23 mg/d
group vs 3.8% in the 10 mg/d group), aggression (2.7%
vs 2.5%), and hallucinations (1.1% vs 0.8%).
Treatment-emergent laboratory abnormalities,
ECG, or vital signs
No clinically important differences between treatment
groups were observed in the proportion of patients with
treatment-emergent abnormal laboratory values or ECG
abnormalities other than bradycardia, or in the magni-
tude or direction of mean change from baseline for any
vital sign parameter.
Demographic and baseline factors:
effect on safety and tolerability
Age
For analysis of the effects of age, the following age
groups were defined: 45-64 years (n = 235), 65-74 years
(n = 440), 75-84 years (n = 643), and 85-90 (n = 116)
years. In both treatment groups, there was a higher rate
of diarrhea and urinary tract infection with increasing
age; in the 23 mg/d treatment group, but not in the 10
mg/d group, fatigue, somnolence, and urinary inconti-
nence also demonstrated this tendency. Interestingly,
t h er a t eo fn a u s e aa n dv o m i t i n gg e n e r a l l yt e n d e dt o
decrease in successively higher age groups among those
receiving 23 mg/d, from 15.6% and 10.5%, respectively,
in the youngest age group to 6.5% and 2.6% in the
highest.
Gender
There were few notable gender differences. There was a
similar high rate of urinary tract infection in women in
both treatment groups (5.9% for 23 mg/d and 5.4% for
10 mg/d) compared with 1.7% in men in both groups.
In the 23 mg/d treatment group specifically, the only
AEs that were noted more frequently in women than in
men were anorexia (6.3% vs 3.7%, respectively) and
weight decrease (5.8% vs 2.8%, respectively). In contrast,
there was a slightly higher incidence in men than in
women of agitation in the 23 mg/d group (5.9% vs 2.8%)
and of aggression in both treatment groups (3.4% vs
2.3% for 23 mg/d and 4.0% vs 1.7% for 10 mg/d).
Race
Because there were too few black and Hispanic patients
to provide meaningful conclusions, comparisons could
be made only between white patients (73.5% of patients
in this analysis) and Asian/Pacific patients (17.3% of
Table 4 Serious AEs that occurred in >0.5% of patients in
either treatment group
Preferred Term Donepezil
23 mg/d
(n = 963)
Donepezil
10 mg/d
(n = 471)
Percentage of patients with at
least 1 serious AE
8.3 9.6
Urinary tract infection 0.6 0.4
Fall 0.6 0.4
Pneumonia 0.3 0.6
Syncope 0.2 1.1
Aggression 0.2 0.8
Confusional state 0.1 0.6
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there were higher incidences of nausea, vomiting, anor-
exia, dizziness, headache, and insomnia among Asian/
Pacific patients than among white patients. This may be
related to Asians having a lower mean baseline weight
(55.1 kg) compared to the total safety population (66.3
kg) (see below).
Weight
In the donepezil 23 mg/d treatment arm, a higher inci-
dence of AEs was observed in the lowest weight group
(≤55 kg, n = 218) compared with each of the 3 higher
weight groups (55 to <65, n = 245; 65 to <75, n = 240;
≥75, n = 259).
Concomitant memantine use
Similar types of AEs were observed in patients regard-
less of memantine use. The patients taking memantine
tended to have more advanced AD at baseline (mean
MMSE score among patients taking memantine was
about 12 points in both treatment groups and about 14
in those not taking memantine). As expected, patients
in both treatment groups who were also taking meman-
tine concomitantly tended to have higher rates of those
A E st h a tw e r ec o m m o n l yo b s e r v e di np a t i e n t sw i t h
more severe disease, such as agitation and falls. Rates of
serious AEs were also slightly higher in both treatment
groups among patients using memantine.
Timing of AEs and discontinuations
Higher dose study
As shown in Table 5, at the end of Week 1 there was a
higher rate of patients reporting any AE and of patients
discontinuing due to AEs in the 23 mg/d group com-
p a r e dw i t ht h eg r o u pt h a tc o n t i n u e dt a k i n g1 0m g / d
(30% and 8.3% vs 12.1% and 1.9%). However, the abso-
lute increase in these percentages was similar in both
groups between Weeks 1 and 2 and again between
Weeks 2 and 4. Finally, there were comparable increases
in the percentage of patients reporting any AE between
W e e k4a n de n do fs t u d yi nt h e2 3m g / da n d1 0m g / d
groups.
Comparison with analysis of pooled data from prior studies
To further examine the effect of donepezil dose up-titra-
tion, rates of AEs associated with initiation of treatment
with 5 mg/d donepezil and with a dose increase from
5 mg/d to 10 mg/d were assessed using pooled data
from 2 pivotal phase 3 trials of donepezil for the treat-
ment of mild to moderate AD [6,7]. Both active treat-
ment groups were initiated on 5 mg/d at baseline. On
study Day 8, the 5 mg group continued taking that
dose, and the comparator group titrated up from 5 mg
to 10 mg. During the first week after starting 5 mg, the
rate of AEs overall and of discontinuations due to AEs
was similar in the placebo and active treatment groups
(Table 6). However, during Week 2, the percentages of
patients with AEs and patients discontinuing due to AEs
both increased markedly in the group that was titrated
to 10 mg/d (absolute increase of 20.7% and 3.5%,
respectively). Such marked increases were not observed
in the 5 mg/d group, which had increases of 6.9% and
0.7%, respectively, comparable to the placebo group
(6.5% and 0.7%, respectively). From the end of Week 2
t ot h ee n do fW e e k4 ,t h ea b s o l u t ei n c r e a s ei nt h ep e r -
centage of patients reporting AEs was once again similar
among all groups (11.2%, 11.8%, and 10.5% in the pla-
cebo, 5 mg/d, and 10 mg/d groups, respectively),
although the percentage of patients discontinuing due to
AEs remained elevated in the 10 mg/d group (0.7%,
0.5%, and 3.2%, respectively). This pattern continued
f r o mW e e k4t ot h ee n do ft h es t u d y ,j u s ta so b s e r v e d
for the 23 mg/d group (Table 4).
Discussion
Both the 23 mg/d and 10 mg/d doses of donepezil used
in the study reported by Farlow et al. were generally
safe and well tolerated. A transient increase in choliner-
gic-related GI AEs was observed in the first 2-4 weeks
Table 5 Cumulative percent of patients with AEs
Donepezil 23 mg/d Donepezil 10 mg/d
1 week 2 weeks 4 weeks Total
duration
1 week 2
weeks
4 weeks Total
duration
Number (%) of subjects with at least 1 such AE 289
(30.0)
347
(36.0)
444
(46.1)
710 (73.7) 57
(12.1)
83 (17.6) 124
(26.3)
300 (63.7)
Number (%) of subjects who discontinued due to
AEs
80 (8.3) 98 (10.2) 122
(12.7)
179 (18.6) 9 (1.9) 16 (3.4) 20 (4.2) 37 (7.9)
Vomiting 68 (7.1) 73 (7.6) 77 (8.0) 89 (9.2) 5 (1.1) 5 (1.1) 5 (1.1) 12 (2.5)
Nausea 92 (9.6) 96 (10.0) 100
(10.4)
114 (11.8) 6 (1.3) 7 (1.5) 9 (1.9) 16 (3.4)
Diarrhea 34 (3.5) 44 (4.6) 57 (5.9) 80 (8.3) 8 (1.7) 11 (2.3) 12 (2.5) 25 (5.3)
Dizziness 26 (2.7) 28 (2.9) 35 (3.6) 47 (4.9) 3 (0.6) 6 (1.3) 8 (1.7) 16 (3.4)
Headache 18 (1.9) 22 (2.3) 30 (3.1) 41 (4.3) 1 (0.2) 2 (0.4) 5 (1.1) 15 (3.2)
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was similar in both treatment groups. AEs usually asso-
ciated with more advanced disease, such as neuropsy-
chiatric symptoms [8], were not clinically significantly
different between the 10 and 23 mg/d groups. There
were no differences between groups in the incidence of
clinically notable abnormal laboratory parameters or
vital signs.
The 23 mg/d dose of donepezil was associated with a
higher rate of AEs, particularly GI-related AEs (nausea,
vomiting, diarrhea, and anorexia), than the 10 mg/d
dose. The transient increase in these cholinergic AEs
observed with initiation of the higher dose is consistent
with the pattern previously seen in studies with a dose
increase from 5 mg/d to 10 mg/d [9]. These results are
in accord with other studies showing that AChEIs as a
class are associated with cholinergic AEs and that the
incidence and severity of these AEs increase when
patients are titrated from a lower to a higher dose regi-
men [2,3]. However, previous studies did not specifically
examine the temporal relationship between dose initia-
tion and AEs.
During the first 2 weeks following upward dose
titration, approximately 20% of patients reported a first
episode of a GI-related AE. A less pronounced rise in
GI-related AEs was also seen during this period in
patients who continued treatment with donepezil 10
mg/d. This finding of early and transient increases in
GI-related AEs following upward dose titration is
consistent with those of previous studies in which GI
AEs were associated with both treatment initiation and
transitions from low-dose to higher dose treatment
[3,4,7,9,10]. These events declined in frequency after 1
month of treatment, or about 2 weeks after steady-state
donepezil levels had been reached [4,9,11]. Indeed, after
1 month, the proportion of patients reporting new
occurrences of GI-related AEs in this trial fell to roughly
3% in both groups, and then remained low, steady, and
similar between groups through Week 24. Discontinua-
tions due to AEs also peaked during the first 2 weeks of
the study in both treatment groups, with a higher
incidence in the 23 mg/d group, and then the rate of
discontinuations declined steadily thereafter. After 2
months of treatment, the rate of discontinuations
remained low, steady, and similar between groups
through Week 24.
Analysis of pooled data from 2 similarly conducted
trials in mild to moderate AD [6,7] demonstrated that
increasing donepezil dose from 5 mg/d to 10 mg/d led
to a temporal pattern of AEs and discontinuations due
to AEs similar to that observed with increasing from 10
mg/d to 23 mg/d. These data suggest that physicians
and other prescribers may anticipate the same overall
timing, type, and severity of AEs when changing
patients’ dose from 10 mg/d to 23 mg/d as has already
been encountered when switching patients from 5 mg/d
to 10 mg/d. No data are currently available to support
an interim dose titration when increasing from donepe-
zil 10 mg/d to 23 mg/d.
Rates of non-GI AEs with the 23 mg/d dose of done-
pezil were generally low but were greater than those
seen with the 10 mg/d dose. Cardiac AEs were infre-
quent with both the 23 mg/d and 10 mg/d doses. Some
studies have shown an increased risk of bradycardia and
syncope in patients treated with AChEIs [12,13]. In the
current study, the overall incidence of bradycardia was
greater in the higher-dose group, and all 8 patients who
discontinued the study due to bradycardia were taking
23 mg/d. However, bradycardia occurred in fewer than
3% of patients in the 23 mg/d group and was not
Table 6 Cumulative percent of patients with AEs (302/304 pooled population)
Placebo Donepezil 5 mg Donepezil 10 mg
1
week
2
weeks
4
weeks
Total
duration
1
week
2
weeks
4
weeks
Total
duration
1
week*
2
weeks
4
weeks
Total
duration
Number (%) of subjects with at least
1 such AE
92
(21.1)
122
(28.0)
171
(39.2)
329 (75.5) 98
(23.1)
126
(29.6)
176
(41.4)
331 (77.9) 118
(27.4)
201
(48.1)
252
(58.6)
361 (84.0)
Number (%) of subjects who
discontinued due to AE
8
(1.8)
11
(2.5)
14
(3.2)
27 (6.2) 5
(1.2)
8 (1.9) 10
(2.4)
20 (4.7) 9 (2.1) 24
(5.6)
38
(8.8)
65 (15.1)
Vomiting 2
(0.5)
2 (0.5) 3 (0.7) 13 (3.0) 7
(1.6)
9 (2.1) 10
(2.4)
17 (4.0) 13
(3.0)
38
(8.8)
47
(10.9)
59 (13.7)
Nausea 6
(1.4)
11
(2.5)
14
(3.2)
25 (5.7) 15
(3.5)
16
(3.8)
19
(4.5)
26 (6.1) 22
(5.1)
62
(14.4)
78
(18.1)
92 (21.4)
Diarrhea 4
(0.9)
6 (1.4) 9 (2.1) 22 (5.0) 9
(2.1)
15
(3.5)
18
(4.2)
42 (9.9) 14
(3.3)
31
(7.2)
45
(10.5)
73 (17.0)
Dizziness 4
(0.9)
8 (1.8) 10
(2.3)
21 (4.8) 8
(1.9)
14
(3.3)
15
(3.5)
28 (6.6) 9 (2.1) 20
(4.7)
26
(6.0)
38 (8.8)
Headache 9
(2.1)
10
(2.3)
19
(4.4)
50 (11.5) 7
(1.6)
11
(2.6)
20
(4.7)
41 (9.6) 17
(4.0)
31
(7.2)
36
(8.4)
57 (13.3)
*Patients received 5 mg per day during Week 1 and titrated to 10 mg/d on the first day of study Week 2.
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Page 6 of 8commonly associated with other sequelae. Weight
decrease as an AE was more common in the 23 mg/d
group, though it occurred in fewer than 5% of patients,
being mild to moderate in 45 patients and severe in
only 1 patient.
Post hoc analyses to explore additional demographic
factors showed that more women than men who
increased dose to 23 mg/d had anorexia and weight loss.
With respect to age, increased dose to 23 mg/d was
associated with a higher incidence of fatigue, somno-
lence, and urinary incontinence in successively higher
age groups. The higher rates of some common AEs
observed in Asian/Pacific patients in both treatment
groups may be related to lower mean weight in this
patient subpopulation, as was found for the lower
weight compared with the higher weight patients in gen-
eral. A higher rate of AEs was observed in patients
receiving memantine regardless of treatment group
assignment, consistent with their more advanced stage
of AD.
The study in which these data were obtained was a
rigorously conducted global clinical trial involving a
large number of patients with moderate to severe AD,
of whom about one third were receiving concomitant
memantine. Strengths of this study include the detailed
temporal analysis, stratification by concomitant meman-
tine use, and high completion rate in both groups.
Limitations include lack of sufficient representation of
Hispanic and black populations to assess potential race-
r e l a t e ds a f e t yo rt o l e r a b i l i t yi s s u e s ,a n da2 4w e e ks t u d y
duration.
Conclusions
In this pivotal clinical study of donepezil 23 mg/d com-
pared with donepezil 10 mg/d comprising more than
1400 patients with moderate to severe AD, donepezil 23
mg/d was shown to have acceptable tolerability and a
favorable safety profile. Although a short-term increase
in the rate of first reports of cholinergic-related GI AEs
was observed during the initial titration phase, after the
first few weeks of treatment the rates were similar in
both the 23 mg/d and 10 mg/d treatment groups
throughout the remainder of the study. The rate of
serious AEs was low in patients treated with donepezil
23 mg/d and was similar to that seen with donepezil 10
mg/d. The 23 mg/d dose of donepezil was not asso-
ciated with any new safety signals. The good safety and
predictable tolerability profile for donepezil 23 mg/d
supports its favorable risk/benefit ratio in patients with
moderate to severe AD.
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